顺铂用于非小细胞肺癌化疗的药动学  

Pharmacokinetics of cisplatin in patients with nonsmall-cell lung cancer

作　　者：安鸿志[1] 于卫江[1] 李杰[2] 张斌[1] 田锋奇[1] 

机构地区：[1]河南省肿瘤医院药剂科,河南郑州450008 [2]河南省肿瘤医院肿瘤研究所,河南郑州450008

出　　处：《中国医院药学杂志》2008年第20期1736-1738,共3页Chinese Journal of Hospital Pharmacy

基　　金：河南省省属科研院所研究专项基金(编号:0541130401)

摘　　要：目的:比较不同顺铂给药方案治疗非小细胞肺癌的顺铂血药浓度及药动学参数变化。方法:16名非小细胞肺癌化疗患者使用顺铂联合长春瑞滨方案治疗,静脉滴注给药,根据顺铂用药方案不同分为高剂量组与低剂量组。高剂量组用药方案:第1,2天顺铂60mg.m-2,第1,8天长春瑞滨25mg.m-2;低剂量组用药方案:第1～5天顺铂20mg.m-2,第1,8天长春瑞滨25mg.m-2。动态采集患者给药前及末次给药后96h内血样本,高效液相色谱法测定给药后顺铂血药浓度,3P97软件计算药动学参数。结果:从0～96h,高剂量组血药浓度显著高于低剂量组(P<0.05),但差异随时间延长逐渐缩小。除AUC外,两组间其他药动学参数差异无显著性,但个体间变异大,变异系数为12.7%～99%。结论:结论AUC值对于顺铂个体化方案设计具有重要参考价值。OBJECTIVE To compare the drug concentration in plasma and the pharmacokinetics parameters of cisplatin in patients with nonsmall-cell lung eancer（NSCLC）. METHODS Cisplatin（DDP） and vinorelbine（NVB） were administered in 16 patients with NSCLC by intravenous drip infusion. 16 patients were divided in two group（high dose group and lower dose group） according to administration of eisplation. High dose group（n = 8） ：DDP 60 mg·m^-2 dland d2, NVB 25 mg·m^-2 dland d8. Lower dose group（n= 8）：DDP 20 mg·m^-2 dl-d5, NVB 25 mg·m^-2 dland d8. High-performance liquid chromatography （HPLC） was used to determine plasma concentration of cisplatin, and the software 3P97 was used for the pharmacokinetic analysis. RESULTS The drug concentration in plasma has no significant difference in two groups at the same time （P〉0. 05） until 96 hour. The difference decreased as the time prolonged. The parameter of pharmacokinetics has no significant difference in two groups except AUC（P〉0. 05）. The coefficient variation was large （CV： 12. 7 %-99% ） among patients. CONCLUSION AUC is important parameters of pharmacokinetics to personalized medicine of cisplatin.

关 键 词：顺铂 非小细胞肺癌 药动学 高效液相色谱法 

分 类 号：R969[医药卫生—药理学]